Executive Committee: Spectral Medical Inc.

Manager
Positions heldSince
Chris Seto

Chris Seto

Chief Executive Officer 01/04/2021
Director of Finance/CFO 02/08/2019
Debra Foster

Debra Foster

Chief Tech/Sci/R&D Officer -
John Kellum

John Kellum

Chief Tech/Sci/R&D Officer 01/03/2021

Composition of the Board of Directors: Spectral Medical Inc.

Director
CommitteesSince
Paul Walker

Paul Walker

Chairman 02/04/2024
Janelle D'Alvise

Janelle D'Alvise

71 year

Audit Committee 12/11/2021
Finance Committee 12/11/2021
Compensation Committee 12/11/2021
HR Committee 12/11/2021
William Stevens

William Stevens

Audit Committee Chair 24/09/2014
Finance Committee Chair 24/09/2014
Jun Hayakawa

Jun Hayakawa

73 year

Governance Committee 31/05/2018
Nominating Committee 31/05/2018
David Feigal

David Feigal

76 year

Audit Committee 22/06/2023
Finance Committee 22/06/2023
Chris Seto

Chris Seto

Director/Board Member
Cristiano Franzi

Cristiano Franzi

63 year

Director/Board Member 01/01/2024

Former Officers and Directors: Spectral Medical Inc.

Insider
Positions held
SinceUntil
Anthony Bihl
Anthony Bihl
Director/Board Member 02/04/2024 07/06/2024
Chairman 01/03/2008 02/04/2024
Independent Dir/Board Member 01/03/2008 02/04/2024
Blair McInnis
Blair McInnis
Director of Finance/CFO 04/04/2022 01/12/2023
John Nosenzo
John Nosenzo
Director/Board Member 04/08/2020 01/10/2023
Independent Dir/Board Member 04/08/2020 01/10/2023
James Funk
James Funk
Director/Board Member 20/06/2022 04/05/2023
Anthony Businskas
Anthony Businskas
Director of Finance/CFO - 31/01/2018
Investor Relations Contact - 31/01/2018
Corporate Secretary - 31/01/2018
Anjan Sidhu
Anjan Sidhu
Sales & Marketing 01/01/2018 -
Koichiro Takeshita
Koichiro Takeshita
Director/Board Member 01/05/2013 05/12/2016
Independent Dir/Board Member 01/05/2013 05/12/2016
Masayuki Kaneko
Masayuki Kaneko
Director/Board Member 02/12/2016 -
Independent Dir/Board Member 02/12/2016 -
Laine M. Woollard
Laine M. Woollard
Director/Board Member 11/03/2010 24/09/2014
Edward E. McCormack
Edward E. McCormack
Director/Board Member 01/05/2006 -
Independent Dir/Board Member 19/10/2011 -
Ronald Ian Lennox
Ronald Ian Lennox
Director/Board Member 19/01/2010 -
Chairman 01/03/2006 19/01/2010
Independent Dir/Board Member 19/10/2011 -
Gualtiero Guadagni
Gualtiero Guadagni
Sales & Marketing 01/05/2013 -
Kevin A. Giese
Kevin A. Giese
Director/Board Member 10/03/2010 -
Independent Dir/Board Member 10/03/2010 -
Michael Cross
Michael Cross
Director/Board Member 14/08/2009 -
Guillermo A. Herrera
Guillermo A. Herrera
Director/Board Member 22/09/2006 -
Independent Dir/Board Member 22/09/2006 -
Gordon E. Peterson
Gordon E. Peterson
Director/Board Member 19/01/2010 -
William L. Koyle
William L. Koyle
Director/Board Member 01/01/1983 -
Henry Friesen
Henry Friesen
Director/Board Member 19/01/2010 -
Peter Lea
Peter Lea
Corporate Officer/Principal 01/01/1995 01/01/1998
Nisar A. Shaikh
Nisar A. Shaikh
Chief Tech/Sci/R&D Officer 19/01/2010 -
Corporate Officer/Principal 19/01/2010 19/01/2010
R. Richard Wieland
R. Richard Wieland
Director of Finance/CFO 01/02/2018 -
Casey Gurfinkel
Casey Gurfinkel
Investor Relations Contact - -
Public Communications Contact 19/01/2010 -
Robert Verhagen
Robert Verhagen
Corporate Officer/Principal 19/01/2010 -
Yahia A. Gawad
Yahia A. Gawad
Chief Tech/Sci/R&D Officer - -
Gina Franky
Gina Franky
Sales & Marketing - -
David Ray
David Ray
Chief Operating Officer - -
Jeff Comer
Jeff Comer
Corporate Officer/Principal - -

Age distribution of managers

Parity Men Women

Male7
Female2

Of which Executive Committee

Male2
Female1

Of which Directors

Male6
Female1
Logo Spectral Medical Inc.
Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.
Employees
29

Departures of Key Persons

Anthony Bihl
-
Anthony Bihl

Chairman

01/03/2008 02/04/2024

Ronald Ian Lennox
-
Ronald Ian Lennox

Chairman

01/03/2006 19/01/2010

SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW